Skip to main content

Drug Interactions between dexamethasone and Verzenio

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dexAMETHasone abemaciclib

Applies to: dexamethasone and Verzenio (abemaciclib)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which are substrates of the isoenzyme. Administration of the moderate CYP450 3A4 inducers efavirenz, bosentan, and modafinil are predicted to reduce the relative potency-adjusted unbound systemic exposure (AUC) of abemaciclib plus its active metabolites by 53%, 41%, and 29%, respectively. Reduced efficacy of abemaciclib may occur. In addition, when two or more medications with similar adverse effect profiles are given concurrently, the likelihood of experiencing these adverse reactions may be increased. For example, coadministration of abemaciclib with other agents that are also associated with liver damage (e.g., bosentan, efavirenz, nevirapine, pexidartinib, repotrectinib) may increase the risk of hepatotoxicity.

MANAGEMENT: Concomitant use of abemaciclib with moderate CYP450 3A4 inducers should generally be avoided. Alternative agents without CYP450 3A4 induction potential should be considered.

References

  1. (2023) "Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company
  2. (2023) "Product Information. Verzenio (abemaciclib)." Eli Lilly Australia Pty Ltd
  3. (2023) "Product Information. Verzenios (abemaciclib)." Eli Lilly and Company Ltd
  4. (2023) "Product Information. Verzenio (abemaciclib)." Eli Lilly Canada Inc
View all 4 references

Drug and food interactions

Moderate

abemaciclib food

Applies to: Verzenio (abemaciclib)

Grapefruit juice can increase the blood levels of abemaciclib. This may increase side effects such as nausea, vomiting, diarrhea, abdominal pain, decreased appetite, mouth sores, blood clots, hair loss, liver problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of grapefruit and grapefruit juice during treatment with abemaciclib. Be sure to take the medication at approximately the same time everyday to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer